In a patient with alanine aminotransferase (ALT) of 117 U/L and aspartate aminotransferase (AST) of 50 U/L, which is the most likely cause: alcoholic liver disease, high‑dose statin therapy, or iron overload (hemochromatosis)?

ALT 117 and AST 50: Most Likely High-Dose Statin or Non-Alcoholic Liver Disease

This pattern (ALT > AST with AST/ALT ratio of 0.43) is NOT consistent with alcoholic liver disease and makes alcohol the least likely diagnosis among your three options. The AST/ALT ratio is the key discriminator here.

The Critical Diagnostic Ratio

The AST/ALT ratio in this case is 50/117 = 0.43, which is highly informative:

• Alcoholic liver disease typically shows AST/ALT ratio ≥2.0 12
• Your patient's ratio of 0.43 is the opposite pattern
• In alcoholic hepatitis, AST is characteristically much higher than ALT, often with ratios >2:1 1
• Even in heavy drinkers without advanced liver disease, ratios rarely exceed 1.0 unless cirrhosis is present 2

This ratio essentially rules out alcoholic liver disease as the primary cause.

Why Not Iron Overload?

Hemochromatosis typically presents with:

• Mild transaminase elevations (both AST and ALT) in >65% of patients 3
• The key diagnostic markers are elevated ferritin AND transferrin saturation >45% 4
• Without these iron studies showing elevation, hemochromatosis is unlikely
• The transaminase pattern alone is non-specific for iron overload 3

You need to check ferritin and transferrin saturation to evaluate for hemochromatosis 4, but the pattern doesn't specifically suggest this diagnosis.

Statin-Induced Hepatotoxicity: The Most Likely Culprit

Mild ALT/AST elevations (<3 times upper limit of normal) are common with statins and do not indicate significant hepatotoxicity 5:

• Your ALT of 117 U/L is likely <3× ULN (assuming ULN ~40 U/L, this is ~3× ULN)
• AST of 50 U/L is minimally elevated
• Recent evidence confirms statins do not significantly affect transaminases in patients with metabolic liver disease over 12 months 6
• Isolated mild transaminase elevations with statins typically do not require discontinuation 5

Important Caveats About Statin Hepatotoxicity:

• True statin-induced liver failure is extremely rare 7
• Most mild elevations represent adaptation rather than injury 56
• If isolated GGT elevation occurs, this is NOT a marker of hepatotoxicity 8
• The pattern here (predominantly ALT elevation) is consistent with mild hepatocellular adaptation

Practical Algorithm for This Patient

1. Obtain complete history focusing on:

   • Exact alcohol intake (current and past, in units/week) 4
   • Duration and dose of statin therapy
   • Metabolic syndrome features (obesity, diabetes, hypertension) 4
   • Other hepatotoxic medications or supplements 9

2. Order core liver aetiology screen 4:

   • Hepatitis B surface antigen and hepatitis C antibody
   • Ferritin and transferrin saturation (for hemochromatosis)
   • Autoimmune markers (ANA, anti-smooth muscle antibody, immunoglobulins)
   • Fasting glucose and lipid panel
   • Abdominal ultrasound

3. Interpretation based on AST/ALT ratio:

   • Ratio <1.0 (as in this case): Consider non-alcoholic fatty liver disease, statin effect, or other non-alcoholic causes 110
   • Ratio ≥2.0: Would suggest alcoholic liver disease 12
   • Rising ratio over time in non-alcoholic disease: May indicate progression to cirrhosis 10

4. Management decision:

   • Do NOT discontinue statin based solely on these mild elevations 56
   • Repeat liver enzymes in 4-8 weeks
   • If ALT rises to >5× ULN, then consider statin dose reduction or temporary discontinuation 9
   • Address underlying metabolic risk factors

Common Pitfall to Avoid

Do not assume elevated transaminases automatically mean statin hepatotoxicity. The most common cause of mild transaminase elevation in patients on statins is underlying non-alcoholic fatty liver disease (NAFLD/MASLD), not the statin itself 6. The cardiovascular benefits of continuing statin therapy typically outweigh the risk from mild transaminase elevations 5.